Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Net Cash Flow rose 16450.02% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 19532.93%. This contributed to the annual value of -$20.2 million for FY2024, which is 8555.76% up from last year.
  • ARS Pharmaceuticals' Net Cash Flow amounted to $8.0 million in Q3 2025, which was up 16450.02% from $11.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Net Cash Flow peaked at $173.2 million during Q4 2022, and registered a low of -$122.7 million during Q1 2023.
  • Over the past 5 years, ARS Pharmaceuticals' median Net Cash Flow value was -$7.6 million (recorded in 2022), while the average stood at $1.8 million.
  • Data for ARS Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 50891.19% (in 2023) and a maximum YoY decrease of 146170.1% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Net Cash Flow stood at $121.5 million in 2021, then skyrocketed by 42.61% to $173.2 million in 2022, then plummeted by 93.97% to $10.4 million in 2023, then rose by 6.91% to $11.2 million in 2024, then dropped by 28.16% to $8.0 million in 2025.
  • Its Net Cash Flow stands at $8.0 million for Q3 2025, versus $11.7 million for Q2 2025 and -$11.0 million for Q1 2025.